FDA approves Abbott's Simcor cholesterol combo drug

Share this article:
The FDA granted approval to Abbott's NDA for Simcor, a fixed-dose combination of Niaspan (extended-release niacin) and simvastatin, the generic version of Merck's Zocor.

The drug is indicated to raise “good” cholesterol and lower “bad” cholesterol and triglycerides in patients.

The approval for Simcor is the first for a cholesterol drug since questions cropped up last month about the effectiveness of Merck and Schering-Plough's Vytorin, which also is based on niacin.

“Simcor is really the first product that allows physicians to treat all three of the lipids at the same time,” said Jim Stolzenbach, head of clinical development for dyslipidemia at Abbott in a published report. Abbott anticipates annual sales of Simcor to hit $500 million.

As with Vytorin, it remains to be seen whether Simcor will be any better at preventing heart attacks or death than the components of the medication alone.

Abbott said it is conducting a study investigating whether Simcor is better than simvastatin or Niaspan alone. The results of that study will be available in 2011.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.